Flexiroam Limited (FRXN) Chart

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Nexus Minerals Ltd managing director Andy Tudor talked with Proactive about the latest exploration success at the Payns Find gold target, part of the company's Wallbrook Gold Project in Western Australia. Tudor described the program as “exciting” following a third air core drilling campaign that confirmed high-grade intercepts and significantly expanded the mineralised footprint. He said, “All of the attributes for a big system are here,” highlighting consistent grades of up to 5.99g/t at the extremities of a 900m by 750m target zone. The air core results revealed both supergene and fresh rock mineralisation, with around 30% of the 163 holes showing elevated geochemistry in the final metre — a strong indicator of a large underlying system. “It’s that grade in the supergene and in the fresh rock that’s got us excited,” Tudor said. He also pointed to the presence of a full suite of alteration minerals — cerussite, rutile, tourmaline, and albite — typically associated with major gold systems in the region. With the air core phase now complete, Nexus is turning to reverse circulation (RC) drill planning. Tudor confirmed that air core drilling would continue regionally, while the company prepares for a comprehensive RC program at Payns Find to test depth extensions down to 120–150m. Visit Proactive's YouTube channel for more company interviews, and don’t forget to like this video, subscribe to the channel, and hit the notification bell for future updates. #NexusMinerals #GoldExploration #ASXStocks #WallbrookProject #PaynsFind #GoldMiningWA #RCDrilling #JuniorMiners #ASXNXM #MiningNews

Element 25 managing director Justin Brown talked with Proactive about the recent completion of the Tokyo Bay HPMSM Facility Scoping Study in partnership with Nissin Chemical Corporation. The company said the results of the scoping study were positive enough to justify advancing the project to the pre-feasibility stage. Brown explained that the Tokyo Bay site offers unique advantages, including a co-located sulfuric acid plant, deepwater port access, and supporting infrastructure critical for high-purity manganese sulfate production. “We took our learnings from the detailed work we’ve done in Louisiana… and converted them to a Japanese setting,” Brown said. He also noted that Japan's regulatory and geopolitical environment makes it an ideal location for refining and supplying the local battery market. Looking ahead, Brown confirmed that Element 25 and Nissin Chemical will conduct deeper engineering and cost analysis under their existing MOU, with a final investment decision targeted for June 2026. The next milestone will be the pre-feasibility study, expected later this year. Brown also discussed how the Tokyo Bay project fits into the company’s broader “design one, build many” strategy, which aims to establish a global network of refineries fed by ethically sourced manganese from Element 25’s Butcherbird mine. In addition to activity in Japan, Brown highlighted ongoing work in Europe and updates on the Butcherbird expansion and Louisiana project, with construction planned to commence later this year. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #Element25 #Manganese #BatteryMetals #TokyoBay #CriticalMinerals #EVSupplyChain #HPMSM #ButcherbirdProject #CleanEnergyMaterials #JapanRefinery #MiningNews #GreenMetals #ProactiveInvestors

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness